secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inhibrx Biosciences, Inc. (INBX)
CIK:        0002007919
Form:       8-K
Filed at:   2025-03-17T23:59:59+00:00
Accession:  0002007919-25-000020
Event type: earnings
Sentiment:  neutral
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Inhibrx reports FY2024 net income of $1.7B driven by spin-off gain; secures $100M loan
--------------------------------------------------------------------------------

- Net income of $1.7B (EPS $114.01 basic) vs net loss of $241.4M in FY2023; gain from Sanofi INBRX-101 sale.
- Cash of $152.6M at Dec 31, 2024; after $100M Oxford loan in Jan 2025, $230.5M as of Feb 28, 2025.
- R&D expense $203.7M (FY2024) vs $191.6M; includes $25.9M stock option acceleration from spin-off.
- G&A expense $127.9M (FY2024) vs $29.4M; includes $68.1M spin-off costs and $15.2M option acceleration.
- Ozekibart Phase 1 CRC data: 1 CR, 3 PRs, median PFS 7.85 mo; expansion cohort enrolling up to 50 patients.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2007919/000200791925000020/0002007919-25-000020-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2007919/000200791925000020/inhibrx-20250317.htm
  HTML page:      https://secwatch.observer/filing/0002007919-25-000020

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer